M. Byakhov

666 total citations
6 papers, 451 citations indexed

About

M. Byakhov is a scholar working on Oncology, Cancer Research and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, M. Byakhov has authored 6 papers receiving a total of 451 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Cancer Research and 1 paper in Cardiology and Cardiovascular Medicine. Recurrent topics in M. Byakhov's work include Cancer Treatment and Pharmacology (5 papers), Breast Cancer Treatment Studies (5 papers) and HER2/EGFR in Cancer Research (4 papers). M. Byakhov is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Breast Cancer Treatment Studies (5 papers) and HER2/EGFR in Cancer Research (4 papers). M. Byakhov collaborates with scholars based in Spain, United States and Russia. M. Byakhov's co-authors include José Baselga, Semiglazov Vf, Pinuccia Valagussa, Milvia Zambetti, Eva Ciruelos, B. Ojeda, W. Eiermann, Luca Gianni, Sergei Tjulandin and Jutta Steinseifer and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Annals of Oncology.

In The Last Decade

M. Byakhov

6 papers receiving 443 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Byakhov Spain	4	376	240	136	66	53	6	451
Henry Taupin Belgium	6	413 1.1×	209 0.9×	111 0.8×	84 1.3×	88 1.7×	7	482
Rochelle Strenger United States	6	370 1.0×	164 0.7×	131 1.0×	60 0.9×	46 0.9×	19	414
Mary-Ann Lindsay United States	5	487 1.3×	182 0.8×	203 1.5×	151 2.3×	162 3.1×	5	588
G. Raab Germany	7	487 1.3×	483 2.0×	67 0.5×	81 1.2×	50 0.9×	19	650
Maria Cristina Figueroa Magalhães Brazil	6	153 0.4×	132 0.6×	54 0.4×	70 1.1×	82 1.5×	22	308
J-Y Pierga France	11	376 1.0×	183 0.8×	67 0.5×	135 2.0×	113 2.1×	53	479
Laurence Hatteville France	8	295 0.8×	74 0.3×	92 0.7×	67 1.0×	70 1.3×	10	384
V. Diéras France	8	261 0.7×	84 0.3×	38 0.3×	65 1.0×	53 1.0×	25	321
Mikhail Byakhov Russia	6	221 0.6×	231 1.0×	29 0.2×	52 0.8×	94 1.8×	19	385
Giuseppa Ferraro Italy	10	261 0.7×	101 0.4×	54 0.4×	205 3.1×	132 2.5×	19	421

Countries citing papers authored by M. Byakhov

Since Specialization

Citations

This map shows the geographic impact of M. Byakhov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Byakhov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Byakhov more than expected).

Fields of papers citing papers by M. Byakhov

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Byakhov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Byakhov. The network helps show where M. Byakhov may publish in the future.

Co-authorship network of co-authors of M. Byakhov

This figure shows the co-authorship network connecting the top 25 collaborators of M. Byakhov. A scholar is included among the top collaborators of M. Byakhov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Byakhov. M. Byakhov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

Baselga, José, Alexey Manikhas, Javier Cortés, et al.. (2014). Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. Annals of Oncology. 25(3). 592–598. 75 indexed citations

Gianni, Luca, W. Eiermann, Semiglazov Vf, et al.. (2014). Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. The Lancet Oncology. 15(6). 640–647. 356 indexed citations

Gianni, Luca, W. Eiermann, Semiglazov Vf, et al.. (2013). Follow-up results of NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with trastuzumab (CT+H) followed by adjuvant H versus CT alone, in patients with HER2-positive locally advanced breast cancer.. Journal of Clinical Oncology. 31(15_suppl). 503–503. 11 indexed citations

Zambetti, Milvia, José Baselga, W. Eiermann, et al.. (2013). Freedom from progression (FFP) by adding paclitaxel (T) to doxorubicin (A) followed by CMF as adjuvant or primary systemic therapy: 10-yr results of a randomized phase III European Cooperative Trial in Operable Breast Cancer (ECTO).. Journal of Clinical Oncology. 31(15_suppl). 537–537. 1 indexed citations

Byakhov, M., et al.. (2011). Late cardiotoxicity in patients with breast cancer after taxane/anthracycline-based neoadjuvant and adjuvant chemotherapy.. Journal of Clinical Oncology. 29(15_suppl). e11582–e11582. 2 indexed citations

Eiermann, W., José Baselga, Semiglazov Vf, et al.. (2008). Hormone-receptor status and likelihood of predicting pathological complete response (pCR) in the NOAH trial of neoadjuvant trastuzumab in patients (pts) with HER2-positive locally advanced breast cancer (LABC). European Journal of Cancer Supplements. 6(7). 115–115. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact